Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY)
:DRREDDY
Holding IN:DRREDDY?
Track your performance easily
Earnings Data
Report Date
Jan 23, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
18.09Last Year’s EPS
15.67Same Quarter Last Year
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 14, 2021
|% Change Since: -8.83%
|Next Earnings Date:Jan 29, 2021
Earnings Call Sentiment|Neutral
Dr. Reddy's Laboratories demonstrated strong overall performance with record quarterly revenue growth, significant progress in Europe, and major investments in R&D and innovation. However, challenges were noted in the North America generics market and specific segments of the India business, alongside regulatory observations from the FDA.Company Guidance
In the third quarter of FY 2025, Dr. Reddy's Laboratories Limited reported consolidated revenue of Rs. 8,359 crores (US$977 million), marking a 16% year-over-year growth and 4% sequential growth. This performance was bolstered by the integration of the Nicotine Replacement Therapy (NRT) business, contributing Rs. 6,605 crores to revenues, with underlying revenue growth of 7.5% year-over-year excluding NRT. The gross profit margin stood at 59%, with Global Generics and Pharmaceutical Services and Active Ingredients (PSAI) margins at 61.3% and 28.6%, respectively. SG&A expenses increased to Rs. 2,412 crores (US$282 million), comprising 28.9% of sales, while R&D investments were Rs. 666 crores (US$78 million), representing 8% of sales, primarily focusing on complex generics and biosimilars. EBITDA grew 9% year-over-year to Rs. 2,298 crores (US$269 million), maintaining a margin of 27.5%. The effective tax rate was 25.1%, with net profit after tax at Rs. 1,413 crores (US$165 million), reflecting a 2% year-over-year and 13% sequential increase, with reported EPS at Rs. 16.94. The company's net cash surplus stood at Rs. 1,603 crores (US$187 million) as of December 31, 2024.Record Quarterly Revenue Achieved
Dr. Reddy's Laboratories delivered its highest-ever quarterly revenues and EBITDA in Q3 FY 2025, with consolidated revenue at Rs. 8,359 crores (US$977 million), marking a 16% year-over-year growth and 4% quarter-over-quarter increase.
Strong Performance in Europe
The European Generic business recorded revenues of $134 million, showing a strong year-over-year growth of 142% and sequential growth of 114%, driven by new product launches and existing product growth.
R&D and Innovation Investments
Continued investment in R&D was highlighted, with Rs. 666 crores (US$78 million) spent, an increase of 20% year-over-year, focusing on complex generics and biosimilars. The company also secured UK marketing authorization for rituximab and filed for denosumab in the U.S. and Europe.
Launch of Innovative Drugs
Launched Toripalimab, an immuno-oncology drug, and Elobixibat, for chronic constipation, in India, aligning with the strategy to improve drug availability and accessibility.
---
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) Earnings, Revenues Date & History
IN:DRREDDY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IN:DRREDDY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Jan 23, 2025 | ₹1296.30 | ₹1289.35 | -0.54% |
| Nov 05, 2024 | ₹1267.95 | ₹1272.55 | +0.36% |
| May 07, 2024 | ₹1252.74 | ₹1244.46 | -0.66% |
| Jan 30, 2024 | ₹1161.90 | ₹1162.26 | +0.03% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) report earnings?
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) is schdueled to report earning on Jan 23, 2025, TBA Not Confirmed.
What is Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time?
Dr. Reddy's Laboratories Ltd. (IN:DRREDDY) earnings time is at Jan 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Dr. Reddy's Laboratories Ltd. stock?
The P/E ratio of Dr. Reddy's Laboratories Ltd. is N/A.
What is IN:DRREDDY EPS forecast?
IN:DRREDDY EPS forecast for the fiscal quarter 2025 (Q4) is 18.09.
---